This SDS adheres to the standards and regulatory requirements of the United States and may not meet the regulatory requirements in other countries.

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : WARFARIN SODIUM
MSDS Number : 130000000699
Product Use : Pharmaceutical application, Rodenticide
Manufacturer : DuPont
1007 Market Street
Wilmington, DE 19898
Product Information : 1-800-441-7515 (outside the U.S. 1-302-774-1000)
Medical Emergency : 1-800-441-3637 (outside the U.S. 1-302-774-1139)
Transport Emergency : CHEMTREC: 1-800-424-9300 (outside the U.S. 1-703-527-3887)
Other information : professional use

SECTION 2. HAZARDS IDENTIFICATION

Emergency Overview
It inhibits prothrombin formation which results in decreased blood clotting capacity.

Warning symptoms:
Abdominal pain Gum bleeding, Nose bleeding, Bruising and haemorrhage formation

Potential Health Effects
Skin
Warfarin sodium : Causes skin irritation. May cause; Pain, burning sensation, itching, redness, swelling, or rash..

Eyes
Warfarin sodium : May cause eye irritation.

Ingestion
Warfarin sodium : Effects due to ingestion may include: Internal bleeding, The product inhibits prothrombin formation which results in decreased blood clotting capacity..

Repeated exposure
Warfarin sodium: May cause harm to the unborn child. Adverse effects from repeated exposure may include: Abnormal blood clotting with easy bruising or bleeding. Internal abdominal bleeding which could produce abdominal pain, bloating, low blood pressure, dizziness, light-headedness, fainting, sweating, shortness of breath, vomiting blood, blood in stools

Target Organs
Warfarin sodium: Bone marrow, Blood

Carcinogenicity
None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, or OSHA, as a carcinogen.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Component</th>
<th>CAS-No.</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin sodium</td>
<td>129-06-6</td>
<td>100 %</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

Skin contact: Wash off immediately with soap and plenty of water while removing all contaminated clothes and shoes. Wash contaminated clothing before re-use. Discard contaminated shoes.

Eye contact: Remove contact lenses. Rinse immediately with plenty of water, also under the eyelids. Call a poison control center or doctor for treatment advice.

Inhalation: Move to fresh air. Oxygen or artificial respiration if needed. Call a physician immediately.

Ingestion: Rinse mouth. Induce vomiting if person is conscious.Immediately give large quantities of water to drink. Never give anything by mouth to an unconscious person. Obtain medical attention.
General advice : Remove from exposure, lie down. When symptoms persist or in all cases of doubt seek medical advice.

Notes to physician : Vitamin K1 is a specific antidote.

SECTION 5. FIRE-FIGHTING MEASURES

Flammable Properties
Flash point : does not flash

Fire and Explosion Hazard : Hazardous decomposition products Carbon dioxide (CO2) Carbon monoxide

Suitable extinguishing media : Water spray, Dry powder, Foam, Carbon dioxide (CO2)

Firefighting Instructions : Wear self-contained breathing apparatus and protective suit. Evacuate personnel to safe areas. Do not allow run-off from fire fighting to enter drains or water courses.

SECTION 6. ACCIDENTAL RELEASE MEASURES

NOTE: Review FIRE FIGHTING MEASURES and HANDLING (PERSONNEL) sections before proceeding with clean-up. Use appropriate PERSONAL PROTECTIVE EQUIPMENT during clean-up.

Safeguards (Personnel) : Evacuate personnel to safe areas. Ensure adequate ventilation. Wear personal protective equipment.

Spill Cleanup : Shovel into suitable container for disposal. Avoid dust formation. Clean contaminated surface thoroughly.

Accidental Release Measures : Do not flush into surface water or sanitary sewer system. Dispose of in accordance with local regulations.

SECTION 7. HANDLING AND STORAGE

Handling (Personnel) : Avoid contact with skin and eyes. Do not breathe dust. Provide appropriate exhaust ventilation at places where dust is formed. Wear self-contained
breathing apparatus and protective suit. Avoid contact with skin, eyes and clothing. Do not breathe dust. Wash hands before breaks and immediately after handling the product. Discard contaminated shoes. Wash contaminated clothing before re-use. Routinely monitor blood clotting capacity of personnel handling this product.

Handling (Physical Aspects) : Keep away from open flames, hot surfaces and sources of ignition.

Storage : Keep containers tightly closed in a cool, well-ventilated place. Keep away from oxidising agents and strongly acid or alkaline materials.

Storage temperature : 15 - 30 °C (59 - 86 °F)

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Engineering controls : Ensure adequate ventilation.

Personal protective equipment
Respiratory protection : In the case of respirable dust, use self-contained breathing apparatus. Respirator with a particle filter (EN 143)

Hand protection : Additional protection: Protective gloves

Eye protection : Tightly fitting safety goggles Face-shield

Skin and body protection : Complete suit protecting against chemicals Complete head face and neck protection Boots Apron

Exposure Guidelines
Exposure Limit Values

None established.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Form : solid, crystalline
Color : white
Odor : none
pH : 7 - 8
Material Safety Data Sheet

WARFARIN SODIUM

Version 2.0

Revision Date 12/16/2010

Ref. 130000000699

Melting point/range: 161 °C (322 °F)
Specific Gravity: 0.24 at 20 °C (68 °F)

SECTION 10. STABILITY AND REACTIVITY

Conditions to avoid: Direct sources of heat. Exposure to light.
Incompatibility: None.
Hazardous decomposition products: Hazardous decomposition products formed under fire conditions.: Carbon monoxide, Carbon dioxide (CO2)
Hazardous reactions: None reasonably foreseeable.

SECTION 11. TOXICOLOGICAL INFORMATION

WARFARIN SODIUM
Skin irritation: no data available
Eye irritation: Moderate eye irritation
Reproductive toxicity: Information given is based on data obtained from similar substances.
Further information: The product inhibits prothrombin formation which results in decreased blood clotting capacity. All symptoms are associated with haemorrhage either into body cavities or tissues.

Warfarin sodium
Dermal LD50: 40 mg/kg, rat
Information given is based on data obtained from similar substances.
Oral LD50: 1.6 mg/kg, rat
Information given is based on data obtained from similar substances.
Oral LD50: 5 mg/kg, rat
Information given is based on data obtained from similar substances.
Inhalation 4 h LC50: 0.005 mg/l, rat
Information given is based on data obtained from similar substances.
Skin sensitization: Did not cause sensitization on laboratory animals, guinea pig. Information given is based on data obtained from similar substances.

Repeated dose toxicity: Human. Target Organs: Blood. Prolonged blood-clotting time, Abnormal formation of blood cells, bone marrow changes. Information given is based on data obtained from similar substances.

Carcinogenicity: Overall weight of evidence indicates that the substance is not carcinogenic. Information given is based on data obtained from similar substances.

Mutagenicity: Did not cause genetic damage in animals. Genetic damage in cultured mammalian cells was observed in some laboratory tests but not in others. Did not cause genetic damage in cultured bacterial cells. Information given is based on data obtained from similar substances.

Teratogenicity: Animal testing showed effects on embryo-foetal development at levels below those causing maternal toxicity. Foetal malformations. Reduced embryo-foetal viability. Information given is based on data obtained from similar substances.

SECTION 12. ECOLOGICAL INFORMATION

Aquatic Toxicity
WARFARIN SODIUM

Cell multiplication inhibition test NOEC:
Scenedesmus capricornutum (fresh water algae) 0.073 mg/l

Growth inhibition NOEC:
Scenedesmus capricornutum (fresh water algae) 0.34 mg/l

Warfarin sodium

96 h LC50:
Oncorhynchus mykiss (rainbow trout) 65 mg/l
Information given is based on data obtained from similar substances.

96 h LC50:
Oncorhynchus mykiss (rainbow trout) 16 mg/l
Information given is based on data obtained from similar substances.
96 h LC50 : Lepomis macrochirus (Bluegill sunfish) 17.5 mg/l
Information given is based on data obtained from similar substances.

48 h EC50 : Daphnia magna (Water flea) 17 mg/l
Information given is based on data obtained from similar substances.

SECTION 13. DISPOSAL CONSIDERATIONS
Waste Disposal : Dispose of as special waste in compliance with local and national regulations.

Environmental Hazards : If recycling is not practicable, dispose of in compliance with local regulations.

SECTION 14. TRANSPORT INFORMATION

DOT
UN number : 3027
Proper shipping name : Coumarin derivative pesticides, solid, toxic
Class : 6.1
Packing group : I
Labelling No. : 6.1
Reportable Quantity : 100 lbs Warfarin sodium

IATA_C
UN number : 3027
Proper shipping name : Coumarin derivative pesticide, solid, toxic (Warfarin sodium)
Class : 6.1
Packing group : I
Labelling No. : 6.1

IMDG
UN number : 3027
Proper shipping name : Coumarin derivative pesticide, solid, toxic (Warfarin sodium)
Class : 6.1
Packing group : I
Labelling No. : 6.1
SECTION 15. REGULATORY INFORMATION

TSCA Status : On the inventory, or in compliance with the inventory

SARA 313 Regulated Chemical(s) : Warfarin sodium

CERCLA Reportable Quantity : 101 lbs
   Based on the percentage composition of this chemical in the product.: Warfarin sodium

SARA Reportable Quantity : 101 lbs
   Based on the percentage composition of this chemical in the product.: Warfarin sodium

California Prop. 65 : Chemicals known to the State of California to cause cancer, birth defects or any other harm: none known

PA Right to Know Regulated Chemical(s) : Substances on the Pennsylvania Hazardous Substances List present at a concentration of 1% or more (0.01% for Special Hazardous Substances): Warfarin sodium

NJ Right to Know Regulated Chemical(s) : Substances on the New Jersey Workplace Hazardous Substance List present at a concentration of 1% or more (0.1% for substances identified as carcinogens, mutagens or teratogens): Warfarin sodium

SECTION 16. OTHER INFORMATION

Contact person : MSDS Coordinator, DuPont Chemicals and Fluoroproducts, Wilmington, DE 19898, (800) 441-7515

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.
Material Safety Data Sheet

WARFARIN SODIUM

Version 2.0

Revision Date 12/16/2010

Ref. 130000000699

Significant change from previous version is denoted with a double bar.